WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2008101002) USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/101002    International Application No.:    PCT/US2008/053836
Publication Date: 21.08.2008 International Filing Date: 13.02.2008
Chapter 2 Demand Filed:    12.09.2008    
IPC:
A61K 9/00 (2006.01), A61K 31/495 (2006.01), A61P 9/00 (2006.01), A61P 3/10 (2006.01)
Applicants: CV THERAPEUTICS, INC. [US/US]; 3172 Porter Drive, Palo Alto, CA 94304 (US) (For All Designated States Except US).
JERLING, Marcus [SE/SE]; (SE) (For US Only).
WOLFF, Andrew [US/US]; (US) (For US Only)
Inventors: JERLING, Marcus; (SE).
WOLFF, Andrew; (US)
Agent: CLARKE, Pauline, Ann; CV Therapeutics, Inc., 3172 Porter Drive, Palo Alto, CA 94304 (US)
Priority Data:
60/889,734 13.02.2007 US
60/893,121 05.03.2007 US
60/894,903 14.03.2007 US
60/914,645 27.04.2007 US
60/941,219 31.05.2007 US
60/947,613 02.07.2007 US
Title (EN) USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
(FR) UTILISATION DE LA RANOLAZINE POUR LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES
Abstract: front page image
(EN)Disclosed is the treatment of patients suffering from cardiovascular diseases with an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.
(FR)L'invention concerne le traitement de patients souffrant de maladies cardiovasculaires à l'aide d'une perfusion intraveineuse (IV) de ranolazine. Selon un mode de réalisation, la perfusion IV de ranolazine est suivie par l'administration par voie orale d'une formulation posologique de ranolazine à libération prolongée afin de maintenir les niveaux de ranolazine dans le plasma humain à des niveaux thérapeutiques chez des patients.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)